Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (31)
NITAG documentation (1591)
Reports (55)
SAGE documentation (222)
Scientific publications (112)
Systematic reviews (SYSVAC) (2853)
Regions
Africa (274)
Americas (766)
Eastern Mediterranean (50)
Europe (705)
South-East Asia (81)
Western Pacific (199)
Diseases
Chikungunya (9)
Cholera (34)
COVID-19 (1513)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (80)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (68)
Hepatitis A (64)
Hepatitis B (157)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (68)
HIV / AIDS (10)
Human papillomavirus (HPV) (493)
Influenza (581)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (28)
Measles (130)
Meningococcal disease (148)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (46)
Pertussis (105)
Pneumococcal disease (277)
Poliomyelitis (86)
Q fever (1)
Rabies (29)
Rotavirus (117)
RSV (Respiratory syncytial virus) (48)
Rubella (64)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (60)
Tick-borne encephalitis (12)
Tuberculosis (77)
Typhoid (24)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4864 results found
2021
∙
Haut Conseil de la santé publique
HAS statement relating to the possibility of carrying out a vaccination schedule with two mRNA vaccines of different specialties in exceptional situations - 29 April, 2021
2021
∙
Haute Autorité de Santé
HAS vaccination strategy against Covid-19 - Place of the COMIRNATY® mRNA vaccine in 12-15 year olds - 03 June, 2021
2021
∙
Kathleen Dooling, ACIP
Implementation considerations for COVID-19 Vaccines
2021
∙
UNITAG
Interim Advisory on the introduction of COVID-19 vaccine booster doses in Uganda
2021
∙
NACI
Interim guidance on booster COVID-19 vaccine doses in Canada
2021
∙
ACIP
Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years
2021
∙
ACIP
Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines
2021
∙
SAGE
Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19
2021
Interim Recommendations on the Use of COVID-19 Vaccines in Nigeria
2021
∙
Sara Oliver, ACIP
Janssen COVID-19 Vaccine - ACIP conclusion
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register